These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 29302899)
1. Salivary Duct Carcinoma and Invasive Ductal Carcinoma of the Breast: A Comparative Immunohistochemical Study. Jalaly JB; Sanati S; Chernock RD; Dibe DG; El-Mofty SK Head Neck Pathol; 2018 Dec; 12(4):488-492. PubMed ID: 29302899 [TBL] [Abstract][Full Text] [Related]
2. Molecular and biomarker analyses of salivary duct carcinomas: comparison with mammary duct carcinoma. Hoang MP; Callender DL; Sola Gallego JJ; Huang Z; Sneige N; Luna MA; Batsakis JG; El-Naggar AK Int J Oncol; 2001 Oct; 19(4):865-71. PubMed ID: 11562768 [TBL] [Abstract][Full Text] [Related]
3. Expression of PTEN, Androgen Receptor, HER2/neu, Cytokeratin 5/6, Estrogen Receptor-Beta, HMGA2, and PLAG1 in Salivary Duct Carcinoma. Liang L; Williams MD; Bell D Head Neck Pathol; 2019 Dec; 13(4):529-534. PubMed ID: 30390196 [TBL] [Abstract][Full Text] [Related]
4. Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors. Truin W; Roumen RMH; Siesling S; van de Vijver KK; Tjan-Heijnen VCG; Voogd AC Breast Cancer Res Treat; 2017 Jul; 164(1):133-138. PubMed ID: 28365833 [TBL] [Abstract][Full Text] [Related]
6. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. Fan CY; Wang J; Barnes EL Am J Surg Pathol; 2000 Apr; 24(4):579-86. PubMed ID: 10757407 [TBL] [Abstract][Full Text] [Related]
7. Androgen receptor immunohistochemistry in salivary duct carcinoma: a retrospective study of 188 cases focusing on tumoral heterogeneity and temporal concordance. Xu B; Dogan S; Haroon Al Rasheed MR; Ghossein R; Katabi N Hum Pathol; 2019 Nov; 93():30-36. PubMed ID: 31430492 [TBL] [Abstract][Full Text] [Related]
8. Expression of Hormone Receptors and HER-2 in Benign and Malignant Salivary Gland Tumors. Can NT; Lingen MW; Mashek H; McElherne J; Briese R; Fitzpatrick C; van Zante A; Cipriani NA Head Neck Pathol; 2018 Mar; 12(1):95-104. PubMed ID: 28681314 [TBL] [Abstract][Full Text] [Related]
9. [Survival analysis and immunohistochemical study of HER-2 and AR (androgen receptor) expression in salivary duct carcinoma]. Otsuka K; Imanishi Y; Habu N; Sato Y; Shigetomi S; Fujii R; Sakamoto K; Tomita T; Fujii M; Kameyama K; Ogawa K Nihon Jibiinkoka Gakkai Kaiho; 2013 Sep; 116(9):1024-32. PubMed ID: 24191589 [TBL] [Abstract][Full Text] [Related]
10. Clinicopathological and immunohistochemical behavior of ductal carcinoma of the salivary and lacrimal gland in a Mexican Mestizo population. Luna-Ortiz K; Dominguez-Malagon H; Corredor-Alonso GE; Reynoso-Noveron N; Herrera-Ponzanelli C; Luna-Peteuil Z; Zacarias-Ramon LC Eur Arch Otorhinolaryngol; 2022 Jan; 279(1):327-333. PubMed ID: 33763743 [TBL] [Abstract][Full Text] [Related]
11. Oncocytic intraductal carcinoma of salivary glands: a distinct variant with TRIM33-RET fusions and BRAF V600E mutations. Bishop JA; Nakaguro M; Whaley RD; Ogura K; Imai H; Laklouk I; Faquin WC; Sadow PM; Gagan J; Nagao T Histopathology; 2021 Sep; 79(3):338-346. PubMed ID: 33135196 [TBL] [Abstract][Full Text] [Related]
12. Salivary Duct Carcinoma: An Update on Morphologic Mimics and Diagnostic Use of Androgen Receptor Immunohistochemistry. Udager AM; Chiosea SI Head Neck Pathol; 2017 Sep; 11(3):288-294. PubMed ID: 28321773 [TBL] [Abstract][Full Text] [Related]
13. Biomarker immunoprofile and molecular characteristics in salivary duct carcinoma: clinicopathological and prognostic implications. Santana T; Pavel A; Martinek P; Steiner P; Grossmann P; Baněčková M; Skálová A Hum Pathol; 2019 Nov; 93():37-47. PubMed ID: 31437521 [TBL] [Abstract][Full Text] [Related]
14. Genomic alteration in rare subtype of sarcomatoid salivary duct carcinoma. Jeong JS; Cho KJ; Kim D; Lee YS; Song JS Pathol Res Pract; 2021 Dec; 228():153678. PubMed ID: 34781210 [TBL] [Abstract][Full Text] [Related]
15. Frankly Invasive Carcinoma Ex-intraductal Carcinoma: Expanding on an Emerging and Perplexing Concept in Salivary Gland Tumor Pathology. McLean-Holden AC; Rooper LM; Lubin DJ; Magliocca KR; Manucha V; Sadow PM; Tobias J; Vargo RJ; Thompson LDR; Heidarian A; Weinreb I; Wenig B; Gagan J; Hernandez-Prera JC; Bishop JA Head Neck Pathol; 2022 Sep; 16(3):657-669. PubMed ID: 34985683 [TBL] [Abstract][Full Text] [Related]
16. Salivary duct carcinoma with rhabdoid features: a salivary counterpart of pleomorphic lobular carcinoma of the breast. Kusafuka K; Kawasaki T; Maeda M; Yamanegi K; Baba S; Ito Y; Inagaki H; Nakajima T Histopathology; 2017 Jan; 70(2):164-173. PubMed ID: 27079821 [TBL] [Abstract][Full Text] [Related]
17. Expression of androgen receptor, gross cystic disease fluid protein, and CD44 in salivary duct carcinoma. Kapadia SB; Barnes L Mod Pathol; 1998 Nov; 11(11):1033-8. PubMed ID: 9831198 [TBL] [Abstract][Full Text] [Related]
18. Expression pattern of androgen receptor and AR-V7 in androgen-deprivation therapy-naïve salivary duct carcinomas. Yang RK; Zhao P; Lu C; Luo J; Hu R Hum Pathol; 2019 Feb; 84():173-182. PubMed ID: 30267779 [TBL] [Abstract][Full Text] [Related]
19. Primary De novo ductal adenocarcinoma of the lacrimal gland. Tripathy D; Agarwal S; Biala A; Rath S; Mittal R Ann Diagn Pathol; 2021 Feb; 50():151651. PubMed ID: 33186791 [TBL] [Abstract][Full Text] [Related]
20. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Steinman S; Wang J; Bourne P; Yang Q; Tang P Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]